Want Explosive Profits in Days? Try Alexander Green’s “No-Brainer” Trading Strategy
Want Explosive Profits in Days? Try Alexander Green’s “No-Brainer” Trading Strategy
In an interview, host, Becky Sattero sat down with America’s #1 insider trading analyst, and The Oxford Club’s Chief Investment Strategist (CIS), Alexander Green to discuss an urgent matter. Brought to light by Alexander, it allegedly pertains to a little-known aviation firm quietly building a $3.1 million position. Interestingly, this company has since secured 500,000 in shares, most of which were purchased during a “three-day buying frenzy late in 2021.”
Expounding further on his discovery, he noted that the shares were mostly purchased by the company’s directors. This is a big deal because these higher officials know everything about the day-to-day operations and the finances. Long story short, Alexander sees this act as “the best “heads-up” an investor can get […] it means one thing […] they think it’s worth a lot more than it’s selling for.”
So far, our editorial team learned that the company’s stock is going for $5, and with the aforesaid trends, prices are unlikely to be positioned this way for long. Moreover:
Alexander’s interest in tracking insider activity spans over almost four decades and in this time, he always concentrated on five types. These include:
When higher executives of a company sell their holdings, it normally implies plummeting of stock prices, and reasons for this can be extensive. Buying on the other hand only means one thing: stock prices are almost certain to skyrocket.
Insider investing only warrants further investigation if members are of top-level, not so much mid-to-lower-level employees. While employees may have some sense of where the company might be headed, they don’t know nearly as much as members at the very top.
Insider buys between $500 and $20,000 are nice to see, but nothing gets the eyes popping like a minimum of $100,000. According to Alexander, the latter will immediately grab his attention over the former.
Small stocks have a higher probability of going up than big stocks, hence the reason why Alexander prefers insider buying among smaller companies. Ultimately, a market cap less than $5 billion coupled with insider trading is enough to “foreshadow a big move higher for the stock.”
Cluster buying is when multiple insiders buy at the same time. This is deemed a strong signal that good news and profits lie ahead for a company.
These very principles all support the previously introduced aviation stock that Alexander landed on. Are you curious to learn more about the investment at hand? This is where it is best fit to introduce The Insider Alert.
The Insider Alert is self-explanatory; it is an investment research advisory where recommendations are made once they meet all the requirements of the five types of insider activities. Insider trading is a vital component to measure when assessing the value of an asset and no one is as equipped as Alexander Green. He affirms to guide everyone through all the steps, from a takeover bid, and product launch right down to the list of earning releases. Although some degree of knowledge can be self-taught, having Alexander take the lead guarantees new insights and investment strategies.
Once individuals are members of The Insider Alert, several doors of opportunity will open. The aforesaid has since been summarized in the following special reports:
The first report has been compiled to educate investors on the previously mentioned $5 private aviation stock. Everything from the company name and financials to the investment specifics such as the ticker symbol and entry and exit points will be outlined here. Alexander will share evidence on healthy insider trading with a thorough analysis.
The financial system has been under spotlight for its outdated practices. Since then, several solutions have taken shape, whether they are centralized or decentralized. Inside this report, Alexander lays down the fundamentals of a company touted as an alternative banking firm reckoned to become a fintech giant. The expert predicts that its value may double in a short period, especially seeing that its CEO, CFO, and CRO have all acquired a combined $467,274 in shares.
The next stock is for speculators only, and it revolves around healthcare. Specifically, the company of interest developed an infertility treatment that Alexander refers to as EIT or “Economical Infertility Treatment”. Why is he convinced by this investment?
Unlike conventional IVF treatments, EIT only costs a fraction (i.e., -33%), which permits lower-income patients with an affordable option. Captivatingly, there only exists one lab in Birmingham, Alabama that tends to people of all financial backgrounds. More on how this $3 infertility cure stock might positively impact one’s model portfolio can be found here.
Besides the above trio, members will be automatically entitled to:
The Insider Alert membership is offered at two different price points determined by the length of the service (promo code: N786Y200). In particular, a one-year membership is currently priced at $1,999 whereas a two-year membership is $2,999. Bear in mind that these are automatically renewed unless customer service is contacted, and the cancellation processes have gone through.
Additionally, Alexander’s guarantee is two-fold. As explained by his team:
“[First] If Alex doesn’t deliver at least ONE 1,000% winner, per his recommendations, call up our VIP Member Services Team – and they’ll give you another year of The Insider Alert ON THE HOUSE. [Second] If Alex doesn’t average one chance to double your money each month over the next year, call up our VIP Member Services Team – and they’ll give you a full refund – minus a 10% processing fee.”
To help individuals with decision-making, Alexander’s team is open to scheduling a call to go through the entirety of The Insider Alert. This option is seldomly offered, so we encourage everyone needing clarification to book an appointment swiftly by clicking here. In the meantime, more information can be gathered in one of the following ways:
By now it should be clear that Alexander Green is The Oxford Club’s CIS (15 years and counting) and the lead editor for The Insider Alert. Fortunately, there’s more to learn about him and let’s just say, he is unlikely to disappoint. Below is a summary of his career:
From what’s been made available thus far, our editorial team was able to muster that Alexander will be using his studied and well-defined indicators that point towards healthy insider trading. Such activity is often celebrated because it implies the anticipation of big news for a company, and thus, its respective stock. While his special reports hint interest in aviation and healthcare, the expert is allegedly open to any industry, which might be beneficial to investors looking to diversify their portfolios.
As someone who has been studying these trends for almost four decades, the opportunity to read his material and to hear from him should be taken advantage of, as it helps to build upon different angles into investing. If these aren’t enough, the two-fold guarantee practically seals the deal, that is to us of course. At the end of the day, investing carries risk that must be assessed along with one’s ability to bear them beforehand. For more on The Insider Alert, visit here>>>.
RELATED:Jeff Brown The Last American Dollar Review (Near Future Report)
The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.
Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.